•
Sep 30, 2023

Bio-Techne Q1 2024 Earnings Report

Bio-Techne's first quarter results for fiscal year 2024 were released, showing revenue growth and strategic progress.

Key Takeaways

Bio-Techne reported a 3% increase in first-quarter revenue to $276.9 million, with organic revenue growth of 2%. GAAP EPS was $0.31, while adjusted EPS was $0.41. The company highlighted strong performance in EMEA and continued growth in key product lines.

First quarter organic revenue increased by 2% to $276.9 million.

GAAP EPS was $0.31, and adjusted EPS was $0.41.

ExoDx prostate test volume increased 49%, and GMP proteins revenue increased 39%.

EMEA region experienced organic growth of 15%.

Total Revenue
$277M
Previous year: $270M
+2.7%
EPS
$0.41
Previous year: $0.45
-8.9%
Organic Sales Growth
2%
Previous year: 7%
-71.4%
Gross Profit
$185M
Previous year: $180M
+3.1%
Cash and Equivalents
$149M
Previous year: $165M
-10.0%
Free Cash Flow
$45.8M
Previous year: $46.5M
-1.6%
Total Assets
$2.76B
Previous year: $2.35B
+17.2%

Bio-Techne

Bio-Techne

Bio-Techne Revenue by Segment

Forward Guidance

No specific forward guidance was provided in the press release.

Revenue & Expenses

Visualization of income flow from segment revenue to net income